Navigation Links
RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
Date:1/14/2014

d on the mRNA that controls production of this protein.

RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies.  This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, including future expectations regarding our NASDAQ listing, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks th
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Diego, CA (PRWEB) November 17, 2014 Athena ... of Salk , Dr. Beverly Emerson, a professor in the ... of genes. Her most recent discovery points to an “off ... Dr. Emerson’s career and how her local research is making ... will present her findings and then join host Cheryl K. ...
(Date:11/18/2014)... Georgia (PRWEB) November 18, 2014 ... (Melbourne, Australia) recently formed a partnership with researchers ... Swinburne University of Technology, and the USDA’s Forest ... components reinforced with nanocellulose. Nanocellulose is a rapidly ... goal of the project is to replace heavy ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
(Date:11/18/2014)... Nev. , Nov. 18, 2014 PDL ... announced that in connection with the acquisition of Durata ... million in connection with the termination of PDL,s credit ... principal amount outstanding of $40 million, accrued interest, and ... PDL entered into a structured financing transaction with Durata ...
Breaking Biology Technology:American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2
... Genesis Biopharma, Inc. (OTC Bulletin Board: ... today announced that President and CEO Robert Brooke will ... Forum Biotech, Healthcare & Pharma Virtual Conference.  The webcast ... p.m. Eastern time (10:00 a.m. Pacific time) by visiting ...
... University have discovered new properties in a material that ... for pollution-free electricity production. The discovery, posted online ... the journal Nature Materials , reveals that energy-carrying ... the order of a thousand times farther in organic ...
... 8 IntegenX, Inc. (IXI) today announced that ... the Defense Threat Reduction Agency (DTRA) of the ... Integrated Sample-to-Sequence (ISS) system for rapid detection and ... relevant bacteria and viruses, and emerging pathogens. IntegenX ...
Cached Biology Technology:Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13 2Rutgers discovery paves way for development of efficient, inexpensive plastic solar cells 2IntegenX Awarded DTRA Contract to Develop Pathogen Detection and Identification Platform 2
(Date:11/3/2014)... DUBLIN , Nov. 3, 2014 Research ... report "Cell Therapy - Technologies, Markets and Companies" ... evaluates cell therapy technologies and methods, which have already started ... Hematopoietic stem cell transplantation is replacing the old fashioned bone ... described. Cell therapy is bound to become a part of ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
(Date:11/2/2014)... fascinating to put a flashlight up to our palms ... University in St. Louis engineers are using a similar ... improve imaging of cancerous tissues and to develop potential ... Beare Distinguished Professor of Biomedical Engineering at the School ... time-reversal technology that allows researchers to better focus light ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... Boston Universitys College of Engineering may have discovered ... defeating so-called superbugs, bacteria that have developed resistance ... previously unknown chain of events occurring in bacteria ... research. Currently, three classes of bactericidal ...
... Efforts to make open-heart surgery a minimally invasive ... Institutes of Health Bioengineering Research Partnership award. Professor ... cardiac surgeon Pedro del Nido, M.D., at Childrens ... Inc. (Van Nuys, CA) will collaborate to develop ...
... says, is an essential peptide factor for the growth ... that this growth factor is important for the nervous ... in the October 7 issue of the World Journal ... about this growth factor: NGF is positively related with ...
Cached Biology News:Boston University biomedical engineers find chink in bacteria's armor 2Boston University biomedical engineers find chink in bacteria's armor 3Minimally invasive heart surgery research wins NIH award 2Targeting nerve growth factor may cure liver cancer 2
... weight determinations for petroleum-based applications. Multiple solvents can be used, such as water, benzene, formamide, ... ... ... ...
Fast, sensitive quantitation of total MEK 1/2 concentration....
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
... Automatic High Sensitivity Laboratory Osmometer for 50 L samples. Operating head automatically rises at the end of ... ... ... ...
Biology Products: